Combining power to accelerate high-fidelity evidence generation
Viewpoint Evidence
Viewpoint Evidence generates unified, longitudinal views of participant health journeys by connecting records across health systems, pharmacies, and personal devices — plus, prospectively and directly engaging them for research that reflects real life.
The Pre Platform
The Pre platform powers Verily precision research, including the core data solutions — Refinery, Exchange, and Workbench. Together, they’re an end-to-end ecosystem for your data value chain, from data discovery and enrichment, to data analysis and AI development.
Unlock efficiencies across your teams
De-risk asset development
Research & development
Assist R&D teams in de-risking their asset validation and accelerating the journey from bench to bedside by enabling go — or no go — decisions with greater speed and confidence.
Plan optimal protocols
Clinical development
Support clinical development teams by designing more relevant, feasible trials to accelerate study timelines and capture the long-term outcomes that matter most to the real-world recipients of your therapy.
Show real-world value
HEOR & market access
Enable HEOR and market access teams to demonstrate real-world economic and quality-of-life impact to payers and regulators by uncovering the reasons that shape complete patient journeys.
Track real-world outcomes
Medical affairs
Empower medical affairs teams to drive scientific credibility and support the medical community by generating a persistent stream of novel, real-world evidence to answer critical post-launch questions.
Reflect patient journeys
Patient engagement
Help patient engagement teams embed the patient voice across the entire product lifecycle by providing a direct, scalable channel to quantify the real-world patient experience.
Hear from Verily experts
From data gaps to dynamic dialogue: A new era of real-world evidence
Listen in with Verily leaders as they explore how Viewpoint Evidence enables connections to engaged, re-contactable individuals, transforming research into a dynamic dialogue.
Our partners
Verily and NVIDIA collaborate to accelerate precision Health AI
Verily and NVIDIA are working together to speed the development of AI agents and models across research and care.
NVIDIA’s AI tech stack will be integrated across Verily’s Pre platform, including NVIDIA NeMo, NVIDIA Parabricks, and NVIDIA CUDA-X Data Science now available in Workbench, with accelerated workflows powered by NVIDIA Blackwell.
Using the Pre platform enhanced with NVIDIA's AI tools, Verily's researchers have developed the first multimodal foundation model using the NIH All of Us Research Program dataset. The model integrates EHR and genomics data using polygenic risk scores for a more holistic health profile.
Verily and a leading pharmaceutical company establish a cornerstone analysis environment
A global pharmaceutical leader and Verily are looking to create a cornerstone analysis environment for internal and external omics data.
Why Workbench
- Data gravity: Workbench provides access to a growing library of critical data with rich discovery and exploration capabilities.
- Scalability and flexibility: Our analysis environment meets the needs of diverse audiences through a dedicated account-scaling model, extensible toolset across data sources, and cost-transparency.
- Compliance and risk: Workbench provides secure controls to meet governance requirements for internal and external data controllers, and is designed for co-analyzing data in owned cloud environments with individualized policy frameworks.
More on optimizing evidence generation
PlaybookWorkbench
Empowering Biopharma: Scaling Data and Analytics for Breakthrough Research
WebinarEvidence
From data gaps to dynamic dialogue: A new era of real-world evidence
BlogEvidence
From data gaps to continuous insight — A persistent evidence engine that reflects real life
Solution sheetEvidence
A more complete view of human health
Solution sheetWorkbench
Catalyze research and development
Solution sheetEvidence
From Baseline to Breakthrough
PublicationEvidence